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Abstract 
Subcellular fractionation was performed on human U251 glioblastoma cultures. In all subcellular fractions, 
the binding of the peripheral benzodiazepine ligand, [3H]PK 11195, correlated with the specific activity of 
monoamine oxidase (r-- 0.95, p < 0.001) and succinate dehydrogenase (r = 0.93, p < 0.001), two mi- 
tochondrial enzymes. The specific activity of plasma membrane and nuclear markers correlated poorly with 
the presence of PK 11195 binding sites. These data support the mitochondrion as the primary location of 
peripheral-type benzodiazepine binding sites (PBBS) in human glioma cells. 
Mitochondria-rich preparations were then assayed for [3H]Ro5-4964 binding. Six nM [3H]Ro5-4964 failed 
to specifically bind to human U251 mitochondria, but bound vigorously to mitochondria from rat C6 glioma. 
These data indicate that the low affinity of Ro5-4864 for PBBS in human glioma cells compared to those in rat 
is due to interspecies receptor variation rather than impaired drug transport into human cells. 
Braestrup and Squires first demonstrated two dis- 
tinct classes of benzodiazepine binding sites in rats 
[1, 2]. The binding sites were named the central 
benzodiazepine receptor (CBR) and the peripheral 
benzodiazepine binding site (PBBS) because of 
their predominance in the brain and non-CNS tis- 
sue respectively. 
Although there are relatively few neuronal or 
glial PBBS, the receptor is abundant in glioma cells 
[3-7]. The high density of PBBS in tumors com- 
pared to normal brain parenchyma serves as the 
basis for positron emission tomographic (PET) 
imaging of human gliomas using the PBBS ligand, 
[llC]PK 11195 [8]. Development of improved PET 
ligands and ligands suitable for single photon emis- 
sion computed tomography (SPECT) or radiother- 
apy requires an understanding of whether or not 
ligands must pass through tumor cell plasma mem- 
brane in order to bind to PBBS. 
Defining the subcellular location of PBBS is also 
an essential step toward understanding the role of 
PBBS in cancer cells. In early studies, micromolar 
concentrations of PBBS ligands were shown to in- 
duce differentiation of Friend erythroleukemia 
cells [9], promote melanogenesis in B16 melanoma 
cells [10] and inhibit proliferation of mouse thymo- 
ma cells [11]. Because the concentration of ligand 
required to affect cell proliferation correlated 
poorly with binding affinitiy, the role of PBBS in 
modulating tumor cell growth was subsequently 
questioned [12]. Recent studies have demonstrated 
that PBBS ligands influence tumor cells at concen- 
trations which are consistent with receptor medi- 
ated actions. Ikezaki and Black reported that nano- 
molar concentrations of PK 11195 induced a mod- 
est increase in C6 rat glioma cell growth rate when 
the cells were grown in serum-free medium [13]. In 
Nb node lymphoma cells, nanomolar concentra- 
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tions of PK 11195 and Ro5-4864 potentiate prolac- 
tin-stimulated proliferation but had no effect in the 
absence of prolactin [14]. PK 11195 and Ro5-4864 
(10 -14 to 10-6M) also inhibit oxygen consumption 
of mouse C1300 neuroblastoma cells [15]. 
The influence of PBBS ligands on neuroblasto- 
ma oxygen consumption supports the hypothesis 
that PBBS modulate mitochondrial respiration. 
PBBS ligands have been shown to influence mi- 
tochondrial respiration in rat kidney [16] and PBBS 
have been localized to mitochondria in rat kidney 
[17] and rat adrenal [18]. Binding sites with nearly 
identical drug binding parameters however, have 
been localized to human erythrocyte membrane 
preparations [19] which lack mitochondria and nu- 
clei [20]. A nuclear location for PBBS has also been 
proposed, but lack of marker enzyme correlation in 
these studies makes it difficult to assess whether 
contaminants were responsible for PBBS ligand 
binding in the nuclear fraction [5, 21, 22]. 
The current study was developed because the 
location of PBBS in human glioma cells cannot be 
extrapolated from relatively few, conflicting re- 
ports of subcellular fractionation studies in non- 
neoplastic rat tissues. In addition, Ro5-4864 bind- 
ing was evaluated in mitochondria-rich prepara- 
tions from human and rat glioma cultures. The 
purpose of this experiment was to determine 
whether the previously reported interspecies dif- 
ference in PBBS affinity for Ro5-4864 and related 
compounds is due to receptor differences versus 
impaired transport of PBBS ligands into human 
cells [23]. 
Materials and methods 
Drugs and chemicals 
Unlabeled PK 11195 was a gift from Dr. G. Le Fur, 
Rhone-Poulenc, Genevilliers, France. Unlabeled 
Ro5-4864 was a gift of Dr. P. Sorter, Hoffman- 
LaRoche, Nutley, NJ. Tritiated PK 11195 (specific 
activity= 75.2Ci/mmol) and Ro5-4864 (specific 
activity = 77.9 Ci/mmol) were purchased from Du 
Pont-New England Nuclear, Boston, MA. [3H]PK 
14105 (specific activity= 81Ci/mmol) was pur- 
chased from Research Products International, 
Mount Prospect, IL. [3H]Thymidine was pur- 
chased from Moravek Biochemicals Inc., Brea, 
CA. [14C]Tyramine was purchased from Amer- 
sham, Arlington Heights, Illinois. Culture media 
and fetal bovine serum were purchased from Gib- 
co, Grand Island, NY. All other chemicals were 
purchased from Sigma, St. Louis, MO. 
Cultures and tissues 
Human glioblastoma line U251 was obtained from 
Dr. Darrel D. Bigner of Duke University. Rat 
glioma line C6 was purchased from American Type 
Culture Collection, Rockville, MD. Cultures were 
grown in minimum essential media supplemented 
with 10% fetal bovine serum at 37 ° C in humidified 
air supplemented with 5% CO2. 
Cell disruption 
All procedures were carried out at 4 ° C. Fraction- 
ation was performed on cells from eighty plates 
(10 cm diameter) of confluent U251 cultures which 
had been grown for 24-36 hours. Monolayers were 
washed with 4 ml 'H buffer' (5 mM HEPES, 0.21 M 
d-mannitol, 0.07M sucrose, 2mM benzamidine, 
2 mM phenyl-methyl-sulfonyl fluoride, and 4 mM 
MgC12, pH = 7.4). Cells were scraped in 15 mls 
homogenization buffer ('H buffer' supplemented 
with 0.2% Nonidet P-40) then ruptured in a 
Dounce glass homogenizer using 15 strokes with a 
Type B pestle. Homogenates were spun at 200 g for 
1 min. The pellet, consisting of cells which were 
resistant to rupture in homogenization buffer, was 
rehomogenized in 4 ml hypotonic homogenization 
buffer (diluted 4 x with distilled water). The ho- 
mogenates were combined and centrifuged at 200 g 
for lmin. Supernatants were strained through 3 
layers of gauze. The resulting slurry was designated 
as the 'homogenate' referred to throughout this 
paper. 
Fractionation 
Two ml of homogenate were reserved for marker 
assays. The remaining homogenate was centri- 
fuged at 600 g for 20 rain. The resulting pellet was 
designated '0.6K'. The supernatant was centri- 
fuged at 15,000 g for 20 min. The pellet was gently 
ground into a paste using an ice-filled test tube. The 
paste was layered over 3ml of 1M sucrose and 
centrifuged for 3 hrs at 40,000 g. The heavy fraction 
which passed through the sucrose cushion was des- 
ignated '15K Hv' and the light membranes which 
remained on top of the cushion were designated as 
'15K Lt'. The supernatant from the 15,000 g spin 
was centrifuged at 100,000 g for 1 hr. The subse- 
quent pellet was designated '100K' and the solution 
which failed to pellet at 100,000 g was designated as 
'Sol'. 
Enzyme assay 
Clorgyline-sensitive monoamine oxidase was 
quantitated using [14C]tyramine as the substrate 
according to the method of Wurtman and Axelrod 
[24]. One percent bovine serum albumin was in- 
cluded in the assay mixture to stabilize monoamine 
oxidase activity. 
Spectrophotometric assays were measured in a 
Perkin-Elmer Lambda 3 Spectrophotometer. Suc- 
cinate dehydrogenase activity was determined by 
measuring the absorption of reduced imidazolium 
nitro-tetrazolium violet (INT), extracted in ethyl 
acetate, at 490nm [25]. Alkaline phosphatase ac- 
tivity was determined by measuring the liberation 
of p-nitrophenol from p-nitrophenylphosphate at 
420 nm as previously described [26]. 
DNA and protein assays 
DNA was quantitated fluorimetrically using 
370nm excitation and 440nm emission wave- 
lengths in a Perkin Elmer Fluorimeter. Samples 
were briefly sonicated before the addition of 
Hoechst dye (butamamide) [27]. Calf thymus 
DNA was used for the standard curve in each ex- 
periment. Protein concentrations were determined 
by the Bradford assay (Biorad, Richmond, CA). 
Bovine serum albumin was used for standards. 
Binding assays 
Samples were incubated for 60min at 4°C with 
6 nM [3H]PK 11195 or 6 nM [3H]Ro5-4864. Assays 
were terminated by vacuum-assisted filtration 
through Schleicher and Schuell #32 glass filters 
which had been treated for 30min in 0.3% poly- 
ethyleneimine [28]. The filters were washed 3 x 
with 5ml of 50mM Tris-C1, pH 7.4. 
37 
Nonspecific binding was determined in the pres- 
ence of 10txM unlabeled PK 11195. When dry, 
filters were placed in 5ml Bio-Safe II scintillant, 
and assayed for tritium by liquid scintillation spec- 
troscopy. 
Purified nuclei preparation 
Monolayers of U251 cells were pulsed with 0.5 
microCuries/ml [3H]thymidine for four hours then 
chased with media five hours prior to fractionation. 
PBBS in adjacent wells of U251 cells were cova- 
lently labeled with the photoaffinity agent [3H]PK 
14105 as described previously [29]. Cells were 
scraped, homogenized, layered over 3 ml of 2.2M 
sucrose [30], and centrifuged at 40,000g for 3 
hours. Fractions, 250 uL each, were collected from 
the top of the cushion using a Buchler gradient 
collector. 
Results 
Various groups have suggested that PBBS are lo- 
calized to mitochondria [17, 18], plasma membrane 
[19, 22] or nuclei [5, 21, 22]. The enrichment of 
markers for these components was compared to the 
enrichment of [3H]PK 11195 binding in each of six 
subcellular fractions (Fig. 1). The enrichment was 
calculated by dividing a marker's specific activity in 
the fraction of interest by the specific activity of the 
marker in the homogenate fraction. The enrich- 
ment of [3H]PK 11195 binding correlated best with 
the enrichment of the mitochondrial markers 
monoamine oxidase and succinate dehydrogenase. 
It was not possible to obtain a single fraction to 
which PK 11195 binding was unique. The correla- 
tion between the specific activity of PK 11195 bind- 
ing and succinate dehydrogenase activity in all frac- 
tions of 3 experiments was near unity (r = 0.95, 
p < 0.001) (Fig. 2). The specific activity of PK 
11195 also correlated with the specific activity of 
monoamine oxidase (r = 0.93, p < 0.001) (Table 
1). No correlation was observed between PK 11195 
binding and alkaline phosphatase activity (Table 
1). 
A positive albeit weak correlation was observed 
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Fig. 1. Enrichment of [3H]PK 11195 binding and of cellular compartment markers in fractionated human U251 glioblastoma cells. Data 
are presented as fold enrichment (specific activity in fraction of interest divided by specific activity m homogenate). Columns represent 
means of four independent experiments, bars = S.E.M. SDH = succinate dehydrogenase, MAO = monoamine oxidase, AP = 
alkaline phosphatase, DNA = deoxyribonucleic acid. 
DNA (Table 1). To determine whether glioma cell 
nuclei contained PBBS, homogenized U251 cells 
which had been prelabeled with either [3H]thymi- 
dine or [3H]PK 14105, a covalent photoaffinity la- 
bel for the PBBS, were centrifuged over a 2.2M 
sucrose cushion. Greater than 90% of the [3H]PK 
14105 was recovered from the top of the cushion 
while more than 90% of the [3H]thymidine was 
recovered in the pellet (Fig. 3). To rule out the 
possibility that [3H]PK 14105 recovery represented 
noncovalently bound drug released from the PBBS 
during centrifugation, homogenates which had not 
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Fig. 2. Correlation between the specific activity of succinate dehydrogenase and PK 11195 binding in fractions of human U251 
glioblastoma cells. Data points represent values from homogenate, 0.6K, 15K-Hv, 15K-Lt, and 100K fractions of four independent 
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Fig. 3. Recovery of [3H]PK 14105-labeled binding sites and [3H]thymidine tagged nuclei following separation of the 0.6K pellet over 
2.2 M sucrose. Cultured cells were labeled with either [3H]PK 14105 or [3H]thymidine prior to homogenization and centrifugation at 
600g. The 0.6K pellet was then centrifuged over a 2.2M sucrose cushion. Columns represent the mean of three independent 
experiments, bars = S.E.M. 
been labeled with [3H]PK 14105 were assayed for 
[3H]PK 11195 binding following centrifugation 
through the sucrose cushion. In two experiments, 
greater than 80% of [3H]PK 11195 binding was 
localized to the topmost fractions while the remain- 
ing [3H]PK 11195 binding was distributed evenly 
throughout the remaining fractions. The paucity of 
[3H]PK 14105 or [3H]PK 11195 binding in the nu- 
clei-rich pellet indicates that PBBS in the 0.6K 
fraction can be accounted for by non-nuclear orga- 
nelle contaminants. 
[3H]Ro5-4864 binding was examined in Hom and 
15K-Hv fractions of human U251 glioblastoma 
cells. In contrast to [3H]PK 11195, total binding of 
6nM [3H]Ro5-4864 could not be distinguished 
from nonspecific binding determined in the pres- 
ence of 10/xM unlabeled PK 11195 (Fig. 4). Control 
experiments were performed using rat C6 glioma 
cells. In these cells, binding of both [3H]PK 11195 
and [3H]Ro5-4864 were largely displaceable by un- 
labeled PBBS ligands (Fig. 4). 
Discussion 
PBBS are more abundant in a number of tumors 
than in the normal tissue from which the tumors 
were derived [3, 4]. The recent demonstration that 
Table 1. Correlation between the specific activity of PK 11195 and subcellular markers 
Marker Compartment Specific activity n 
r p 
Succinate dehydrogenase Mitochondria 0.95 < 0.001 24 
Monoamine oxidase Mitochondria 0.93 < 0.001 24 
DNA Nucleus 0.57 < 0.025 24 
Alkaline phosphatase Plasma membrane 0.03 < 0.05 24 
The quantity of [3H]PK 11195 binding was compared to the specific activity of succinate dehydrogenase, monamine oxidase and alkaline 
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Fig. 4. [3H]PK 11195 and [3H]Ro5-4864 binding to Horn and 15K-Hv fractions of human U251 and rat C6 glioma cells. Fractions were 
incubated in the presence of 6 nM [3H]PK 11195 or [3H]Ro5-4864 in the presence of 10 tzM unlabeled PK 11195 (blank) or vehicle (total). 
Columns represent the mean of 3 independent experiments, bars = S.E.M. 
ligands which bind to PBBS are capable of mod- 
ulating mitochondrial respiration in rat kidney rais- 
es the question of whether PBBS modulate tumor 
cell respiration [16]. Indeed tumor cells have differ- 
ent energy requirements than normal cells [31, 32]. 
Furthermore,  these requirements must be met by 
fewer mitochondria per cell than in normal tissues 
[31]. The first step in determining whether PBBS 
play a role in tumor cell mitochondrial respiration 
is to determine whether or not the binding site is 
present on the organelle. 
Although convincing evidence suggests that 
PBBS are localized to mitochondria in rat adrenal 
[18] and kidney [17], this finding cannot be general- 
ized to other tissues or species. Human erythro- 
cytes, which lack mitochondria [33], exhibit a PK 
11195 binding site which is pharmacologically indis- 
tinguishable from rat adrenal PBBS [19]. 
The results presented in this paper support the 
hypothesis that PBBS are located primarily on mi- 
tochondria in human glioma cells. PK 11195 bind- 
ing correlated with mitochondrial enzyme recovery 
while no correlation was observed between PK 
11195 binding and the plasma membrane marker 
alkaline phosphatase. Although there was a mod- 
est correlation between DNA content of fractions 
and the recovery of PK 11195 binding, these two 
markers could be separated by centrifugation of 
nuclei through a 2.2 M sucrose cushion. It is impos- 
sible to rule out the presence of a small population 
of non-mitochondrial PBBS due to the difficulty in 
obtaining contaminant-free fractions of individual 
organelles. 
The localization of PBBS to mitochondria of 
glioma cells may have implications in the areas of 
tumor bioenergetics, glioma imaging and the de- 
velopment of new antitumor strategies. The effects 
of PBBS ligands on tumor cell growth and differ- 
entiation might be explained by an action such as 
the modulation of cellular respiration. Indeed, na- 
nomolar concentrations of PK 11195 and Ro5-4864 
suppress oxygen consumption in mouse C 1300 
neuroblastoma cells [15]. The relative abundance 
of high affinity PBBS on mitochondria of tumor 
cells encourages consideration of PBBS ligands as 
carriers of radioisotopes or cytotoxic agents to the 
interior of tumor cells. The fact that drugs must 
pass through the plasma membrane to reach equi- 
librium with mitochondrial receptors limits the size 
and chemical composition of agents that might be 
linked to PBBS ligands. 
This study also demonstrates that mitochondrial 
PBBS in U251 cells fail to bind [3H]Ro5-4864 even 
in the absence of a plasma membrane barrier or 
cytoplasmic components. This finding supports the 
hypothesis that interspecies or intertissue differ- 
ences in the ability of PBBS to bind Ro5-4864 are 
due to differences at the binding site rather than 
differential drug uptake, drug metabolism, or the 
presence of endogenous inhibitors of the Ro5-4864 
domain [23]. 
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